

Ionut Bebu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4762676/publications.pdf>

Version: 2024-02-01

42
papers

970
citations

471061

17
h-index

454577

30
g-index

42
all docs

42
docs citations

42
times ranked

1585
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 875-882.	4.3	114
2	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1969-1977.	2.2	93
3	Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. <i>Biostatistics</i> , 2016, 17, 178-187.	0.9	77
4	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 883-890.	4.3	76
5	The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. <i>Diabetologia</i> , 2017, 60, 2084-2091.	2.9	62
6	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 867-874.	4.3	61
7	Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 436-445.	5.5	56
8	D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. <i>PLoS ONE</i> , 2016, 11, e0152588.	1.1	50
9	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1284-1289.	4.3	42
10	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 854-861.	2.2	37
11	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 657-664.	4.3	32
12	Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 529-535.	1.4	30
13	Application of the Wei's Lachin multivariate one-directional test to multiple event-time outcomes. <i>Clinical Trials</i> , 2015, 12, 627-633.	0.7	25
14	Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. <i>Journal of Lipid Research</i> , 2019, 60, 1432-1439.	2.0	24
15	The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2225-2230.	4.3	21
16	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1499-1505.	4.3	20
17	Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108235.	1.1	20
18	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 2478-2484.	4.3	19

#	ARTICLE	IF	CITATIONS
19	Immune Complexes and the Risk of CVD in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1853-1860.	0.3	15
20	Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 659-665.	4.3	14
21	Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002667.	1.2	12
22	Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108591.	1.1	9
23	Optimal screening schedules for disease progression with application to diabetic retinopathy. <i>Biostatistics</i> , 2018, 19, 1-13.	0.9	9
24	Study of emotional distress in a comparative effectiveness trial of diabetes treatments: Rationale and design. <i>Contemporary Clinical Trials</i> , 2021, 107, 106366.	0.8	7
25	Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 1779-1787.	4.3	7
26	Generalized Confidence Intervals and Fiducial Intervals for Some Epidemiological Measures. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 605.	1.2	6
27	Parametric cost-effectiveness inference with skewed data. <i>Computational Statistics and Data Analysis</i> , 2016, 94, 210-220.	0.7	5
28	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 682-690.	2.4	4
29	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes. <i>Ophthalmology</i> , 2021, 128, 554-560.	2.5	4
30	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2021, 44, 1309-1316.	4.3	4
31	Properties of composite time to first event versus joint marginal analyses of multiple outcomes. <i>Statistics in Medicine</i> , 2018, 37, 3918-3930.	0.8	3
32	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> 2020;69:291-299. <i>Diabetes</i> , 2020, 69, e7-e8.	0.3	3
33	Probabilistic measures of cost-effectiveness. <i>Statistics in Medicine</i> , 2016, 35, 3976-3986.	0.8	2
34	Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. <i>Diabetes</i> , 2020, 69, 2440-2445.	0.3	2
35	Models to Assess the Association of a Semiquantitative Exposure With Outcomes. <i>American Journal of Epidemiology</i> , 2020, 189, 1573-1582.	1.6	2
36	Inference for Surrogate Endpoint Validation in the Binary Case. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 1272-1284.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Closed testing using surrogate hypotheses with restricted alternatives. PLoS ONE, 2019, 14, e0219520.	1.1	1
38	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care, 2022, 45, 585-593.	4.3	1
39	Environmental data analysis based on the gamma distribution: compliance assessment using tolerance limits and exceedance fractions. Environmetrics, 2016, 27, 370-376.	0.6	0
40	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664. Diabetes Care, 2019, 42, e137-e137.	4.3	0
41	The minimum intensity of a mixed exposure that increases the risk of an outcome. Statistics in Medicine, 2020, 39, 4016-4024.	0.8	0
42	Cost-efficient clinical studies with continuous time survival outcomes. Statistics in Medicine, 2021, 40, 3682-3694.	0.8	0